It is in Chicago that the annual high mass of oncology opens this Friday. For the first time, the Asco (American Society of Clinical Oncology) will be held virtually due to the Covid-19. The race between Big Pharma has not weakened. More than 2,200 studies, validated by Asco before the health crisis, will be presented. Oncology remains the world's leading pharmaceutical industry market with $ 150 billion in spending generated in 2018 according to the Iqvia Institute (on a total market of 1,200 billion). It is expected to reach 240 billion by 2023.
Read also: The pharmaceutical industry in full revolution
"As Asco attests this year, the market should be driven by a second wave of immunotherapy treatments, whether they are combinations of treatments or new molecules," comments Michaël Lukasiewicz, medical director of Roche Pharma France. . Many hopes are also focused on targeted therapies and in particular on the genomic approach which makes it possible to identify common mutations
This article is for subscribers only. You still have 69% to discover.
Subscribe: € 1 the first month
cancellable at any time
Enter your emailAlready subscribed? Log in